The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective. (September 2020)

• Record Type: Journal Article
• Authors: Alroughani, Raed; Van Wijmeersch, Bart; Al Khaboori, Jabber; Alsharoqi, Isa Ahmed; Ahmed, Samar F.; Hassan, Ali; Inshasi, Jihad; Krieger, Derk W.; Shakra, Mustafa; Shatila, Ahmed Osman; Szolics, Miklos; Khallaf, Mohamed; Ezzat, Aly
• Is Part Of: Therapeutic advances in neurological disorders. Volume 13(2020)
• Publication Date: 2020-09
• Subjects: alemtuzumab -- disease modifying therapies -- Gulf region -- multiple sclerosis -- patient profiles -- relapsing-remitting; Nervous system -- Diseases -- Periodicals; Nervous system -- Degeneration -- Periodicals; Nervous system -- Diseases -- Treatment -- Periodicals; Nervous System Diseases -- therapy -- Periodicals; Neurodegenerative Diseases -- Periodicals; Système nerveux -- Maladies -- Périodiques; Système nerveux -- Dégénérescence -- Périodiques; Système nerveux; Système nerveux -- Maladies -- Traitement -- Périodiques; 616.805
• DOI: 10.1177/1756286420954119
• Languages: English
• ISSNs: 1756-2856

Abstract

Over the past decade, the development of high-efficacy disease-modifying therapies (DMTs) has been responsible for more effective management of relapsing-remitting multiple sclerosis (RRMS). However, the gaps in optimal care for this complex disease remain. Alemtuzumab (Lemtrada®) is a highly efficacious DMT that shows better patient outcomes and therapeutic benefits, but its use is under-recognized in the Gulf region. Experts in the care of multiple sclerosis shared their opinions based on study data and daily clinical experience in identifying the appropriate patient profile suitable for alemtuzumab's therapeutic benefits. Age, disease activity and severity, disability status, physician experience, and economic condition are some of the key indicators for alemtuzumab use.